HRI谐波C2/C3与心气虚严重程度分级的剂量-反应关系:循证映射与方法学边界

Written by

in

Language

Evidence level: B

一、导言

王唯工团队提出的”桡动脉谐波共振理论”将寸关尺脉搏波分解为心、肝、脾、肺、肾等器官对应的C1-C10谐波分量(PMID: 35161551, 36509825)。后续多篇脉象客观化研究将HRI(谐波比指数)作为脉象分类与证候预测的核心特征(PMID: 33903610, 36294440, 42305919)。然而,既有研究多停留在”二分类关联”——即”心气虚 vs 非心气虚”——的层次;少有研究探索心气虚的轻、中、重分级与HRI谱型之间是否存在剂量-反应曲线。

本文目的是:(1) 系统梳理现有HRI-心气虚证据链及其分级证据缺口;(2) 提出可在多中心、前瞻性框架下检验的剂量-反应研究问题;(3) 明确区分研究假设与已证实结论,并写明证据边界。

本映射为研究草案(draft),不构成临床诊断或治疗建议。心气虚的临床诊断需以《中医临床诊疗术语》或《中药新药临床研究指导原则》为准。

二、文献证据回顾

2.1 HRI向量与心气虚的二分类证据

近五年的脉象客观化研究表明,PPG或压电式脉象仪采集的桡动脉波,经傅里叶分解后获得的C1-C10谐波比值(C2/C1、C3/C1、C4/C1…)可作为脉象分类与脏腑映射的特征向量。Liang等(PMID: 33903610)在120例心气虚 vs 120例对照的多中心横断面研究中显示,HRI向量中心气虚组的C2/C1显著降低、C3/C1显著升高,AUC分别为0.78与0.75。Xu等(PMID: 36294440)在HRI向量与中医证候的多类分类中,心气虚与其他四脏虚证之间的总体分类准确率为71.3%。

这些结果支持HRI向量与心气虚存在显著相关,但研究设计均为横断面或回顾性,无法确定:(a) 严重程度分级与HRI分量的连续关系;(b) 干预后HRI是否随证候逆转而恢复;(c) 不同辨证标准下的分级结果是否对应同一HRI漂移轨迹。

2.2 心气虚分级量表与阈值

心气虚严重程度的临床分级目前主要参考三类工具:
– 《中医临床诊疗术语·证候部分》(2023修订版):以主症(心悸、气短、自汗)、次症(神疲、面色少华)的有无及严重度进行4级评分。
– 《中药新药临床研究指导原则》(2002):心气虚分轻、中、重度,对应症候积分阈值。
– MDPI 2024年Simple Qi Deficiency Score(PMID: 39157688, MDPI 62/7/1421):单一维度气虚筛查量表,α=0.64 / ω=0.63,作为气虚普筛工具。

这些量表在条目构成、权重分配与阈值划定上缺乏统一标准,同一个患者在不同量表下可能被划入不同的严重度等级。因此”剂量-反应”研究必须在入组时固定一个参考量表,并在敏感性分析中比较其他量表结果。

2.3 HRI向量的方法学约束

  • 压力归一化:按压力度直接影响HRI各阶分量幅度。PCHR算法与压力反馈装置的实测显示(PMID: 27314975, 27861248, 31730401),未做压力补偿的HRI向量在跨操作者间的ICC可低至0.3-0.5。
  • 设备差异:不同品牌脉象仪的PPG/压电传感器频率响应不一致,跨设备HRI向量需做Z-score标准化或域适应校正(参见同池#49 P3-EXP-022)。
  • 采集体位与时辰:卧位 vs 坐位、辰时 vs 酉时的HRI向量在子午流注节律下存在漂移(参见同池#5、#15)。

因此剂量-反应研究若不锁定采集条件,结果不可解释。

三、剂量-反应研究问题

基于以上证据缺口,本研究提出三组可证伪的剂量-反应问题:

3.1 主假设(H1)

心气虚轻、中、重三组的HRI-C2/C1呈单调递增或单调递减趋势,C3/C1呈相反方向趋势;趋势性检验(Cochran-Armitage或Jonckheere-Terpstra)p<0.01,调整年龄、性别、BMI后β绝对值>0.3。

3.2 备择假设(H2)

HRI谱型与心气虚分级之间不存在线性剂量-反应关系,仅在轻 vs 重度的二分类中可观察差异。这将提示HRI是”状态标志”而非”严重度连续指标”。

3.3 零假设(H0)

HRI各分量与心气虚分级独立相关,关联主要由混杂因素(如年龄、心率、合并用药)驱动。

四、方法学要点

  1. 样本量与设计:建议采用三阶段设计(详见P3-EXP-035):
    – 阶段1:N=200心气虚确诊患者 + 100健康对照,建立HRI-分级参考曲线。
    – 阶段2:N=600多中心前瞻队列,验证曲线在外部人群的可重复性。
    – 阶段3:N=120干预随访,追踪中药/针灸干预后HRI与证候积分的同步变化。
  2. 采集条件标准化:固定卧位、固定按压力度区间(建议2.5-3.5N,浮沉中取力)、固定采脉时辰(避开子午流注峰值漂移窗口,参考同池#15)。
  3. 量表统一:以《中药新药临床研究指导原则》(2002)为主量表,1993/2017/2023标准为敏感性分析。
  4. 混杂控制:年龄、性别、BMI、心率、合并用药(β受体阻滞剂、ACEI/ARB、利尿剂)作为协变量进入回归模型。
  5. 多重比较:C1-C10共10个分量 × 3个分级组对,需做Bonferroni或FDR校正。
  6. 证伪条件:若阶段2的Cochran-Armitage p>0.05 且AUC增量<0.05,则否定主假设,研究转向H2/H0的方向。

五、证据边界与未解问题

  • 因果方向不明:横断面研究无法区分”HRI漂移是心气虚之果”还是”心气虚之因”。
  • 辨证标准漂移:不同标准下的分级可能映射到不同HRI漂移轨迹,需明确锁定。
  • HRI的设备依赖性:跨设备HRI向量目前无统一校准标准(同池#49 P3-EXP-022未完成)。
  • 人群异质性:合并心血管病、糖尿病、肾病的患者HRI基线本身已偏移,需要亚组分析或排除。
  • 干预后逆转模式未知:中药复方(生脉散、参附汤)是否能在HRI向量上产生可量化的”逆转轨迹”,目前仅有零星病例报告。

六、相关阅读

七、证据与局限

  • 优势:首次系统提出HRI-C2/C3与心气虚分级剂量-反应的研究问题,并写出可证伪的统计学框架。
  • 局限:现有证据全部为横断面或回顾性(PMID: 33903610, 36294440, 35161551, 36509825, 42305919),剂量-反应曲线的”曲线形状”本身是研究目标而非已证实;HRI向量的压力归一化、跨设备校准均未完成(同池#29 P3-EXP-015, #32 P3-EXP-016, #35 P3-EXP-017、#49 P3-EXP-022);心气虚辨证标准的版本漂移是结构性边界。
  • 下一步:完成实验设计P3-EXP-035;推进HRI跨设备校准与压力归一化(同池#32、#35、#49);在锁定辨证标准与采集条件后启动多中心前瞻研究。

证据等级 B(间接证据链);本映射不构成已证实结论。

免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Dose-response relationship between HRI harmonic C2/C3 and severity grading of heart qi deficiency: evidence mapping and methodological boundaries

Evidence level: B

I. Introduction

The “radial artery harmonic resonance theory” proposed by the Wang Weigong team decomposes the radial pulse wave into harmonic components C1-C10 corresponding to organs such as the heart, liver, spleen, lungs, and kidneys (PMID: 35161551, 36509825). Subsequent studies on the objectification of pulse patterns utilize the HRI (Harmonic Ratio Index) as a core feature for pulse classification and syndrome prediction (PMID: 33903610, 36294440, 42305919). However, existing research largely remains at the level of “binary association”—distinguishing between “heart qi deficiency vs. non-heart qi deficiency”—with few studies exploring whether a dose-response curve exists between the graded severity of heart qi deficiency (light, moderate, severe) and HRI spectral types.

The purpose of this paper is: (1) to systematically review the existing evidence chain linking HRI to heart qi deficiency and identify gaps in graded evidence; (2) to propose a dose-response research question testable within a multi-center, prospective framework; and (3) to clearly distinguish between research hypotheses and established conclusions, while defining evidence boundaries.

This mapping serves as a research draft and does not constitute clinical diagnosis or treatment advice. Clinical diagnosis of heart qi deficiency must follow the Terminology for Clinical Diagnosis and Treatment in Traditional Chinese Medicine or the Guiding Principles for Clinical Research of New Chinese Patent Medicines.

II. Review of Literature Evidence

2.1 Binary Evidence of HRI Vectors and Heart Qi Deficiency

Recent studies on the objectification of pulse patterns (within the last five years) indicate that radial artery waves collected via PPG or piezoelectric sensors, when decomposed via Fourier analysis, yield harmonic ratios (C2/C1, C3/C1, C4/C1…) that serve as feature vectors for pulse classification and zang-fu mapping. Liang et al. (PMID: 33903610) demonstrated in a multi-center cross-sectional study involving 120 cases of heart qi deficiency versus 120 controls that the HRI vector showed a significant decrease in C2/C1 and a significant increase in C3/C1 for the heart qi deficiency group, with AUCs of 0.78 and 0.75, respectively. Xu et al. (PMID: 36294440) reported an overall classification accuracy of 71.3% between heart qi deficiency and other four-organ deficiency syndromes within a multi-class classification framework using HRI vectors.

These results support a significant association between the HRI vector and heart qi deficiency, yet study designs remain cross-sectional or retrospective, failing to determine: (a) the continuous relationship between graded severity and HRI components; (b) whether HRI recovers as the syndrome reverses following intervention; and (c) whether grading results under different differentiation standards map to the same HRI drift trajectory.

2.2 Grading Scales and Thresholds for Heart Qi Deficiency Severity

Current clinical grading of heart qi deficiency severity primarily relies on three tools:
– Terminology for Clinical Diagnosis and Treatment in Traditional Chinese Medicine · Syndrome Section (2023 Revision): Utilizes a 4-point scoring system based on the presence and severity of main symptoms (palpitations, shortness of breath, spontaneous sweating) and secondary symptoms (fatigue, pale complexion).
– Guiding Principles for Clinical Research of New Chinese Patent Medicines (2002): Categorizes heart qi deficiency into light, moderate, and severe levels corresponding to specific syndrome score thresholds.
– MDPI 2024 Simple Qi Deficiency Score (PMID: 39157688, MDPI 62/7/1421): A single-dimension qi deficiency screening scale with $\alpha=0.64$ / $\omega=0.63$, serving as a universal screening tool for qi deficiency.

These scales lack unified standards regarding item composition, weight allocation, and threshold setting; consequently, the same patient may be categorized into different severity levels under different scales. Therefore, “dose-response” research must fix a reference scale at enrollment and compare results across other scales in sensitivity analyses.

2.3 Methodological Constraints of HRI Vectors

  • Pressure Normalization: Pressure directly influences the amplitude of each harmonic component in the HRI vector. PCHR algorithms and measurements using pressure feedback devices show (PMID: 27314975, 27861248, 31730401) that HRI vectors without pressure compensation can have inter-operator ICCs as low as 0.3–0.5.
  • Device Variability: Inconsistent frequency responses across PPG/piezoelectric sensors in different brands of pulse instruments necessitate Z-score standardization or domain adaptation correction for cross-device HRI vectors (see Pool #49 P3-EXP-022).
  • Posture and Time of Collection: HRI vectors exhibit drift under the Shi Zi Liu Zhu (sub-microstreaming) rhythm depending on posture (supine vs. sitting) and time of day (Chen hour vs. You hour; see Pool #5, #15).

Therefore, dose-response research results are uninterpretable unless collection conditions are locked.

III. Dose-Response Research Questions

Based on the above evidence gaps, this study proposes three falsifiable dose-response questions:

3.1 Primary Hypothesis (H1)

The HRI-C2/C1 in the light, moderate, and severe groups of heart qi deficiency shows a monotonic increasing or monotonic decreasing trend, while C3/C1 shows the opposite direction; trend tests (Cochran-Armitage or Jonckheere-Terpstra) yield $p<0.01$, and the absolute value of $\beta$ exceeds 0.3 after adjusting for age, gender, and BMI.

3.2 Alternative Hypothesis (H2)

There is no linear dose-response relationship between HRI spectral types and heart qi deficiency grading, with differences observable only in the binary light vs. severe classification. This would suggest HRI acts as a “state marker” rather than a “severity continuous indicator.”

3.3 Null Hypothesis (H0)

Each HRI component is independently associated with heart qi deficiency grading, with associations driven primarily by confounding factors (e.g., age, heart rate, concomitant medications).

IV. Methodological Considerations

  1. Sample Size and Design: A three-stage design is recommended (see P3-EXP-035):
    • Stage 1: N=200 confirmed heart qi deficiency patients + 100 healthy controls to establish an HRI-grading reference curve.
    • Stage 2: N=600 multi-center prospective cohort to verify curve reproducibility in external populations.
    • Stage 3: N=120 intervention follow-up to track synchronous changes in HRI and syndrome scores following herbal medicine/acupuncture interventions.
  2. Standardization of Collection Conditions: Fix supine posture, fix pressure range (recommended 2.5–3.5N, floating/sinking/moving force), and fix pulse-taking time (avoid peak drift windows of Shi Zi Liu Zhu, refer to Pool #15).
  3. Scale Unification: Use the Guiding Principles for Clinical Research of New Chinese Patent Medicines (2002) as the primary scale; use 1993/2017/2023 standards for sensitivity analysis.
  4. Confounding Control: Include age, gender, BMI, heart rate, and concomitant medications (beta-blockers, ACEI/ARB, diuretics) as covariates in regression models.
  5. Multiple Comparisons: With 10 components (C1-C10) × 3 grading groups, apply Bonferroni or FDR correction.
  6. Falsification Criteria: If Stage 2 yields Cochran-Armitage $p>0.05$ and AUC increment <0.05, reject the primary hypothesis, shifting the research direction toward H2/H0.

V. Evidence Boundaries and Unresolved Issues

  • Unclear Causal Direction: Cross-sectional studies cannot distinguish whether “HRI drift is the consequence of heart qi deficiency” or “heart qi deficiency is the cause.”
  • Drift in Differentiation Standards: Grading under different standards may map to different HRI drift trajectories, requiring explicit locking.
  • Device Dependence of HRI: No unified calibration standard exists for cross-device HRI vectors currently (Pool #49 P3-EXP-022 remains incomplete).
  • Population Heterogeneity: Patients with concomitant cardiovascular disease, diabetes, or renal disease exhibit baseline HRI shifts themselves, necessitating subgroup analysis or exclusion.
  • Unknown Reversal Pattern Post-Intervention: Whether herbal formulas (Sheng Mai San, Shen Fu Tang) can produce a quantifiable “reversal trajectory” on the HRI vector remains supported only by scattered case reports.

VI. Related Reading

VII. Evidence and Limitations

  • Strengths: First systematic proposal of a dose-response research question linking HRI-C2/C3 to heart qi deficiency grading, accompanied by a falsifiable statistical framework.
  • Limitations: All existing evidence is cross-sectional or retrospective (PMID: 33903610, 36294440, 35161551, 36509825, 42305919); the “curve shape” of the dose-response relationship is a research goal rather than an established fact; pressure normalization and cross-device calibration of HRI vectors remain incomplete (Pool #29 P3-EXP-015, #32 P3-EXP-016, #35 P3-EXP-017, #49 P3-EXP-022); version drift in heart qi deficiency differentiation standards constitutes a structural boundary.
  • Next Steps: Complete experimental design P3-EXP-035; advance cross-device calibration and pressure normalization (Pool #32, #35, #49); initiate multi-center prospective research after locking differentiation standards and collection conditions.

Evidence Level B (Indirect Evidence Chain); This mapping does not constitute an established conclusion.


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *